SQUAWK/NEWS
Account
Account
Menu
Live NewsCategoriesequity

Neurocrine Biosciences, Inc. (NBIX) News

Track canonical SquawkNews coverage tagged to NBIX, Neurocrine Biosciences, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 7 indexed stories across 5 publication days and is ordered by the same first-publication timeline used by LiveCast.

Symbol NBIX Asset equity Sector Markets 90 days 7 Last 161.96 Updated Aug 12, 2026, 09:35 AM UTC Open live news feed
H NBIX Drug Vykat XR Linked to Deaths NBIX's Vykat XR is linked to deaths and severe side effects, experts warn EQUITY | Aug 12, 2026, 09:35 AM UTC H NBIX Raised to $119.98 at RBC RBC raises NBIX price target EQUITY | Jul 31, 2026, 12:12 PM UTC H NBIX price target raised to $204 NBIX price target raised to $204 from $200 EQUITY | Jul 31, 2026, 09:45 AM UTC L NBIX NBIX - Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results NBIX NBIX - Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results EQUITY | Jul 30, 2026, 08:01 PM UTC L NBIX Neurocrine Biosciences RESULTS: Q2, Q2 ADJ EPS $2.85 vs. EST $1.34, Q2 EPS $1.39, Q2 ADJ Net Income $297M vs. EST $141.4M, Q2 Net Incom NBIX Neurocrine Biosciences RESULTS: Q2, Q2 ADJ EPS $2.85 vs. EST $1.34, Q2 EPS $1.39, Q2 ADJ Net Income $297M vs. EST $141.4M, Q2 Net Income $144M EARNINGS | Jul 30, 2026, 08:01 PM UTC L Neurocrine Biosciences Insider Sold Shares Worth $2,603,112, According to a Recent SEC Filing () -- Ingrid Delaet, Chief Regulatory Officer, on July 07, 2026, sold 14,571 shares in Neurocrine Biosciences (NBIX) for $2,603,112. Following the Form 4 filing with the SEC, Delaet has control over a total of 16,225 com REGULATION | Jul 10, 2026, 08:02 AM UTC L Neurocrine Biosciences Initiates Phase 2 Clinical Study To Assess Crinecerfont In Children Aged 3 Months To Under 4 Years With Classic Conge Neurocrine Biosciences, Inc. (NASDAQ: NBIX ) today announced the initiation of its Phase 2 clinical study to assess the safety and tolerability of crinecerfont in children aged 3 months to under 4 years with classic cong EQUITY | Jul 01, 2026, 08:08 PM UTC